Pharmaceutical Technology

DECEMBER 5, 2022

With the establishment of this Translational Science Hub, Queensland is set to become an international messenger ribonucleic acid (mRNA) vaccine hub. With an initial focus on enchaining mRNA technology and developing a vaccine for Chlamydia, the research at the hub is anticipated to commence in the first quarter of next year.

Vaccines 98

Vaccines Communication Immunization 98

Pharmaceutical Technology

NOVEMBER 30, 2022

in a project agreement from the US government for developing self-amplifying RNA (saRNA) vaccine technology against advanced and emergent viral threats. Development of vaccines to Phase I trials under the five-year $59m prototype project comprises additional $28.4m in milestone payments. By Cytiva Thematic.

Vaccines 59

Vaccines Communication 59

Pharmaceutical Technology

APRIL 25, 2023

As the prophylactic landscape for malaria has changed in recent years with vaccine approvals, major issues still remain with ensuring access in remote communities. However, making sure the vaccine reaches everyone can be challenging due to the storage requirements. The Mosquirix vaccine contains two vials.

Vaccines 69

Vaccines Pharmaceutical Companies Pharmaceutical Companies Communication 69

Digital Pharmacist

JANUARY 16, 2023

National Influenza Vaccination Week: December 6-12. Cervical Health Awareness Month | S hare downloadable content from the NCCC and advocate for HPV vaccinations. World Immunization Week | Post a flyer and share a list on social media of your vaccination offerings. . National Diabetes Month. COPD Awareness Month.

Immunization 98

Immunization Vaccines Communication Hospitals 98

Pharmaceutical Technology

DECEMBER 15, 2022

The Singapore Government has launched Biologics Pharma Innovation Programme Singapore (BioPIPS), which aims to increase the country’s manufacturing capacity for biologics, including recombinant proteins and vaccines. Download the full report to understand what to expect and how to align your strategies for success. By GlobalData.

Vaccines 105

Vaccines Packaging Pharmaceutical Companies Pharmaceutical Companies 105

Pharmaceutical Technology

MARCH 24, 2023

Since the first human administration of the Bacillus Calmette-Guérin vaccine in 1921, no one has been able to successfully follow the vaccine’s path to become the next approved vaccine to tackle tuberculosis (TB). However, as the TB-related death toll remains high, the global need for another vaccine is steadily rising.

Vaccines 64

Vaccines Health and Personal Care Stores Immunization Communication 64

Pharmaceutical Technology

MAY 4, 2023

After a winter marked by a rise in hospitalisations due to the RSV, the FDA has granted its first approval for an Respiratory Syncytial Virus (RSV) vaccine to GSK’s Arexvy for adults ages 60 years and above. This vaccine specifically prevents RSV-related lower respiratory tract disease (LRTD).

Vaccines 64

Vaccines FDA Communication Immunization 64

Pharmaceutical Technology

JANUARY 20, 2023

In 2020, Moderna made a net loss of $747 million while its investigational mRNA vaccines were under development. However, during the Covid-19 pandemic, the US-based biotech rose to prominence as it was one of the first companies to develop Covid-19 vaccines with its mRNA technology. billion in Covid-19 vaccine sales.

Vaccines 98

Vaccines Communication FDA 98

Pharmaceutical Technology

MARCH 23, 2023

China’s National Medical Products Administration (NMPA) has granted emergency use authorisation (EUA) for CSPC Pharmaceutical Group’s messenger RNA (mRNA) vaccine, SYS6006, to treat Covid-19. With this regulatory approval, CSPC Pharmaceutical is claimed to be the first company to receive approval for providing an mRNA vaccine in the country.

Vaccines 52

Vaccines Communication 52

Pharmaceutical Technology

FEBRUARY 1, 2023

RSV researchers at major pharmaceutical companies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. Pharmaceutical companies are pushing to develop drugs and vaccines for RSV with these populations in mind.

Vaccines 64

Vaccines Pharmaceutical Companies Pharmaceutical Companies FDA 64

Pharmaceutical Technology

DECEMBER 13, 2022

To develop a vaccine and then get as many people vaccinated as quickly as possible. Advanced monitoring and analysis technology has enabled more than 13 billion COVID-19 vaccinations to be distributed worldwide to date. In an ever-changing environment, more robust and scalable communications solutions are required.

Vaccines 52

Vaccines Communication Documentation 52

Pharmaceutical Technology

MAY 1, 2023

After a long period of inactivity in RSV vaccine development , two pharmaceutical companies are now approaching regulatory decisions for their RSV vaccines. Both Pfizer and GSK have major approval decisions regarding the use of their RSV vaccines for older adults this May. What incentivises a country to cover a vaccine?

Vaccines 52

Vaccines Nursing Homes Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

MARCH 1, 2023

Oragenics and Inspirevax have signed a license agreement to develop the former’s lead intranasal vaccine candidate for Covid-19, NT-CoV2-1. As part of the exclusive international agreement, Oragenics agreed to pursue the vaccine development with the new BDX301 intranasal mucosal adjuvant of Inspirevax.

Vaccines 52

Vaccines Communication 52

Pharmaceutical Technology

APRIL 24, 2023

Since then, the field of nanomedicine has steadily progressed to reach high points such as the successful use of nanotechnology to deliver messenger RNA (mRNA)-based Covid-19 vaccines. In the case of most mRNA vaccines, a lipid nanoparticle-based approach was chosen due to its ability to protect the mRNA in the body and prevent degradation.

Vaccines 59

Vaccines Immunization Medical Schools FDA 59

Pharmaceutical Technology

MAY 30, 2023

million government grant from the Flanders Innovation & Entrepreneurship (VLAIO) agency that will be used to fuel the company’s vaccine platform, per a 30 May announcement. The company’s prophylactic yellow fever vaccine is part of its plasmid-launched live attenuated virus (PLLAV) platform. AstriVax has received a €2.5

Vaccines 52

Vaccines Communication 52

Pharmaceutical Technology

DECEMBER 8, 2022

Prefilled syringes are increasingly being recognised as the safest method of packaging injectable drugs, and they offer a number of advantages when administering vaccines specifically. Please check your email to download the Whitepaper. Lessons from the Pandemic: Building a Better Prefilled Syringe. By Datwyler. United Kingdom.

Packaging 98

Packaging Vaccines Communication 98

Pharmaceutical Technology

APRIL 12, 2023

The Association of the British Pharmaceutical Industry (ABPI) also states that “the use of animals in medical research has played and continues to play an essential role in the development of new medicines and vaccines”. The topic of animal testing remains a fiercely contentious topic in the public eye.

Vaccines 98

Vaccines FDA Pharmaceutical Companies Pharmaceutical Companies 98

Pharmaceutical Technology

JUNE 13, 2023

Common treatment options for the condition include bladder removal surgery, chemotherapy and/or administration of the BCG vaccine in the bladder. According to GlobalData, Adstiladrin is one of six therapies approved for the treatment of non-muscle invasive bladder cancer in the US, including two BCG vaccines.

FDA 98

FDA Vaccines Chemotherapy Communication 98

Pharmaceutical Technology

MARCH 27, 2023

National Resilience will use the funding to establish a significant domestic biomanufacturing capacity and capabilities for vaccines, nucleic acids including mRNA, and biologics including antibodies, proteins and multi-specifics. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Vaccines 52

Vaccines Communication 52

Pharmaceutical Technology

JANUARY 5, 2023

The swift development of COVID-19 vaccines was an unprecedented scientific and collaborative achievement by government, regulators, research institutions, and the pharmaceutical industry. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies. By GlobalData. United Kingdom.

Vaccines 69

Vaccines Communication Labelling 69

Pharmaceutical Technology

MARCH 29, 2023

Pharmaron is receiving a £151 million investment in capital to support the growth of operations in Liverpool, quadrupling production capacity for gene therapy and vaccine components. Download the full report to understand what to expect and how to align your strategies for success. Please check your email to download the Report.

Communication 110

Communication Vaccines 110

Pharmaceutical Technology

DECEMBER 1, 2022

Its development pipeline comprises chimeric antigen receptor (CAR)-T cell therapies, CD47 immune checkpoint inhibitor and Guanylyl Cyclase C (GCC) cancer vaccine. The GCC Vaccine is being analysed in Phase II clinical trials. By Cytiva Thematic.

Immunization 52

Immunization Vaccines Communication 52

Pharmaceutical Technology

MARCH 20, 2023

The mRNA technology that enabled the largest and fastest vaccine rollout in history is the tip of the innovation iceberg. Poolberg Pharma is deploying AI algorithms on early-stage clinical data to prioritise and reposition vaccine candidates for respiratory syncytial virus. Download the whitepaper to find out more.

Vaccines 90

Vaccines Communication Hospitals 90

Pharmaceutical Technology

MAY 22, 2023

There is a stark difference in favour of the UK biotech ecosystem in terms of expenses compared to the US biotech ecosystem, and specifically the New England region, says Mark Leuchtenberger, CEO of Oxford-based company SpyBiotech, a vaccine developer that plans to study a human cytomegalovirus infection vaccine in H2 2023.

Vaccines 111

Vaccines Compounding Communication 111

Pharmaceutical Technology

MARCH 22, 2023

Among other things, supply chain optimisation, maintaining access to affordable vaccines, and supporting innovation for unmet clinical needs will be the discussion topics, she adds. Download the full report to understand what to expect and how to align your strategies for success. Please check your email to download the Report.

Packaging 105

Packaging FDA Pharmaceutical Companies Pharmaceutical Companies 105

Pharmaceutical Technology

FEBRUARY 3, 2023

With scientists fervently developing mRNA vaccines, nucleic acid therapeutics, and viral vector-based gene therapies, clinicians are set to have a growing number of tools available to treat a wide range of conditions, from infectious diseases to genetic disorders and more. The field of genomic medicine has reached a true turning point.

Communication 97

Communication Packaging Dosage Vaccines 97

Digital Pharmacist

FEBRUARY 1, 2024

Encourage physical activity with this downloadable guide from the CDC. The CDC recommends that people with heart disease be up-to-date with eligible flu, COVID-19, and RSV shots as well as pneumococcal vaccinations to protect against diseases such as pneumonia, meningitis, and bloodstream infections.

Vaccines 52

Vaccines Communication 52

ISPE

MARCH 1, 2023

Biopharmaceutical active ingredients, such as anti-cancer drugs, insulin, vaccines and infusions are produced in these highly complex, "tailor-made" facilities. Previous Slide ◀︎ Next Slide ▶︎ Download White Paper To download this white paper, complete the form below. Leave this field blank

Communication 52

Communication Vaccines 52

ISPE

FEBRUARY 1, 2023

Biopharmaceutical active ingredients, such as anti-cancer drugs, insulin, vaccines and infusions are produced in these highly complex, "tailor-made" facilities. Previous Slide ◀︎ Next Slide ▶︎ Download White Paper To download this white paper, complete the form below. Leave this field blank

Communication 52

Communication Vaccines 52

ISPE

JANUARY 3, 2023

Biopharmaceutical active ingredients, such as anti-cancer drugs, insulin, vaccines and infusions are produced in these highly complex, "tailor-made" facilities. Download White Paper. To download this white paper, complete the form below. You may unsubscribe from these ISPE communications at any time. Company Name.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Communication Vaccines 52

Pharmaceutical Technology

JANUARY 25, 2023

The global vaccine rollout would never have taken place without the advances in visibility and control over supply chains that it necessitated. Controlant’s real-time visibility platform and command center is already transforming vaccine distribution by meticulously tracking shipments from origin sites to vaccination hubs.

Vaccines 59

Vaccines Pharmaceutical Companies Pharmaceutical Companies Communication 59

Pharmaceutical Technology

FEBRUARY 15, 2023

To ensure temperature-critical medicines such as vaccines are fit for purpose, cold chains must be carefully monitored, and products tracked throughout the entire journey from manufacturer to patient. To learn more, download the paper below. [i] Please check your email to download the Report.

Vaccines 52

Vaccines Communication 52

Pharmaceutical Technology

JUNE 6, 2023

With two historic FDA approvals for RSV vaccines in the last two months, this issue’s lead interview addresses the pertinent question of access— how to ensure eligible individuals across the world get this vaccine. Download the full report to understand what to expect and how to align your strategies for success.

Vaccines 52

Vaccines FDA Communication 52

Pharmaceutical Technology

APRIL 27, 2023

The successful development and deployment of the mRNA-based COVID-19 vaccines has catalysed the biopharma industry and paved the way to expand this drug modality to new therapeutic areas. Excluding vaccines, there are five mRNA therapeutic products in clinical trial development as of November 2022.

Vaccines 52

Vaccines Documentation Communication 52

Pharmaceutical Technology

SEPTEMBER 15, 2022

The increase in the production of biological drugs such as vaccines, gene and cell therapies, and monoclonal antibodies, is increasing the volume of injectable drug products in the global healthcare market.

Documentation 40

Documentation Pharmaceutical Companies Pharmaceutical Companies Communication 40

Pharmaceutical Technology

MARCH 21, 2023

Source: GlobalData Pharmaceutical Intelligence Center Clinical trial catalysts In late January, AC Immune released positive interim results from the Phase I/II trial (NCT05462106) studying the company’s vaccine in patients with prodromal Alzheimer’s disease. Please check your email to download the Report.

Packaging 59

Packaging FDA Vaccines Communication 59

Pharmaceutical Technology

FEBRUARY 20, 2023

During the pandemic, Teddy Lab Wuxi have supported over dozens of COVID drug or vaccine clinical trials, many of which are working closely with Cerba Research, and as a result, multiple candidates have been approved under emergency use in different countries. Please check your email to download the Whitepaper.

Research Laboratories 52

Research Laboratories Vaccines Pharmaceutical Companies Pharmaceutical Companies 52